RYVEX LLC has partnered with some of the top brands in the industry and together we are confident that our Haematology Portfolio guarantees a high level of accuracy when identifying differential cells, blood cells disorders and malignancies yet maintaining low operation costs and reduced downtime.
Through our partnership with Beckman Coulter and Alifax we are committed to offering the latest technology to to meet the demands of an evolving health care system
-
Streamline workflow and maximize staff walkaway time with the DxH 690T haematology analyser. This 5-part differential CBC analyser helps you give your patients rapid results, while enabling your technologists to simplify processes and reduce manual tasks. The benchtop system includes the same automated capabilities and industry-leading 93% first-pass yield of our full-featured DxH 900 haematology analyzer,1 as well as support for the Early Sepsis Indicator (ESId) haematology biomarker for sepsis. Available exclusively for mid-volume laboratories on the DxH 690T, the ESId helps clinicians identify sepsis in the emergency department (ED) to support faster, targeted treatment.
-
The right results, the first time The DxH 900 hematology analyzer enables your high-volume laboratory to achieve superb RBC, PLT and WBC differentials through near native-state cellular characterization. Industry-leading 93% first-pass yield* ensures predictable costs and a faster break-even point. Streamlined processes help your laboratory maximize staff time through the most reportable results per square meter in the industry, fewer slide reviews and high system reliability for greater uptime.
